Biotech | December 09, 2025
AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
HYMPAVZI’s safety profile was generally favorable
While Merck can appeal, Halozyme said it expects the order to hold
76 of 180 long COVID-associated genes also linked to ME
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Subscribe To Our Newsletter & Stay Updated
